To April 2013 I chaired the Chlamydia Screening Advisory Group for Department of Health, England. several authors (GH, CI, KF) were either members of this group or provided data and/or support through their roles in the Health Protection Agency. Since that time I have mainatined an informal advisory role to NCSP through the Director. I had no part in the planning, execution or analysis of this study.
REVIEW RETURNED
25-Jul-2014
GENERAL COMMENTS
This study asks local authority commissioners some important questions about use of their resources to screen for gonorrhoea, the patient information offered and confirmation of reactive results before treatment. The response rate was good, and the group present evidence they had considered if the respondents were representative. The exercise to estimate confirmed positive and false positive results resulted in a very wide range of possible cases; the fact that the mean diagnosis rate based on CTAD was higher in areas using the dual tests could be explored or explained further. Were all of these high prevalence areas? The figure 1 indicating mean gonorrhoea diagnoses is rather complex and confusing-not sure it helps explain the point. perhpas better labelling might help? The paper makes two important points that were not clearly stressed: that less than half LAs responding provided specific information about gonorrhoea screening, and that predictive values of screening for gonorrhoea in low prevalence areas were extremely low, with implications for resource allocation in managing unconfirmed reactive tests and for the personal toll on an individual's sexual wellbeing if tested reactive.
REVIEWER

Jane Hocking
University of Melbourne Australia REVIEW RETURNED 13-Aug-2014
GENERAL COMMENTS
Thank you for asking me to review this paper that is investigating the use of dual tests for chlamydia and gonorrhoea on samples collected through the National Chlamydia Screening Programme. Given the increased availability of dual tests now and the potential issues around test performance for gonorrhoea in low prevalence populations, this paper is very timely and will be of great interest to policy makers and those working in the field. There is an urgent need for policy/guidelines around the use of these dual tests. • Please explain what happens to a patient diagnosed with gonorrhoeait seems from the paper, that those diagnosed with gonorrhoea are often referred to a GUM clinic for management/follow up.
3) Results • IMD -please don't use this acronym. I found the number of acronyms confusing and it would easier for the reader if some are explained.
• Please consider including a figure that shows the relationship between underlying gono prevalence and the number of false positive results that could arise assuming a set sensitivity and specificity…..it could be a simple column graph with prevalence on the x axis. 4) Discussion • Top of page 9 -do you mean "powered" instead of "powerful"?
VERSION 1 -AUTHOR RESPONSE
Response to Reviewer 1
This study asks local authority commissioners some important questions about use of their resources to screen for gonorrhoea, the patient information offered and confirmation of reactive results before treatment. The response rate was good, and the group present evidence they had considered if the respondents were representative.
-We'd like to thank the reviewer for their supportive comments about the study and its importance.
The exercise to estimate confirmed positive and false positive results resulted in a very wide range of possible cases; the fact that the mean diagnosis rate based on CTAD was higher in areas using the dual tests could be explored or explained further. Were all of these high prevalence areas? -The reviewer raises an important point here. We aimed for conservative estimates of the number of false positive cases and this led to a wide range in the estimates produced, but we felt this approach accurately reflects the uncertainty in undertaking these estimates. We have added a sentence to the methods section on p.6 to better explain our rationale: "Using this figure, we estimated the absolute number of unconfirmed reactive tests and the number of confirmed diagnoses, using published specificity estimates for a commercial dual test assay.
[21] We did this for two scenarios for the overall prevalence of gonorrhoea in community-based settings, 0.1% and 1.0%, which represent plausible minimum and maximum values."
In relation to the comment about mean diagnosis rates, we found that dual testing was being deployed in most of the LA areas with high GUM diagnosis rates but also in many areas with low GUM diagnosis rates (as indicated by Fig 1) , and that there were three LAs with very high GUM diagnosis rates where dual testing was not being done. We highlight these findings in the Results on p.7/8, "Nevertheless, most LAs had low gonorrhoea diagnosis rates that were below 50 per 100,000 (Figure 1 ). We noted three LAs where dual tests were not being used, all in London, where GUM gonorrhoea diagnosis rates were above 100 per 100,000, placing these areas inside the top ten percent nationally", and in the Discussion on p.10, "Conversely, we also show that dual tests are not being used in some high prevalence areas that might benefit from targeted gonorrhoea screening". We hope these sentences cover the reviewer's comments. Figure 1 indicating mean gonorrhoea diagnosis is rather complex and confusing-not sure it helps explain the point. Perhaps better labelling might help? -Thanks for this comment. We agree that the graph could be clearer. We have redrawn the graph and amended the labelling accordingly.
The paper makes two important points that were not clearly stressed: (1) that less than half LAs responding provided specific information about gonorrhoea screening, -Although less than half of LAs reported using specific gonorrhoea screening patient information leaflets, we found that most of those not providing specific materials reported that gonorrhoea was discussed in their NCSP patient information leaflets (p.8). Since only one LA reported providing no gonorrhoea information in any format, we feel that it might be unfair to LAs to unduly stress this point.
(2) That predictive values of screening for gonorrhoea in low prevalence areas were extremely low, with implications for resource allocation in managing unconfirmed reactive tests and for the personal toll on an individual's sexual wellbeing if tested reactive.
-We agreeand would like to ask for permission (with acknowledgement) to paraphrase the reviewer's wording, which is very helpful, to highlight this point. The text on p.9 now reads: "If dual tests are used, there are important implications for resource allocation in managing unconfirmed reactive tests and for the personal toll on an individual's wellbeing if the test is not confirmed; confirmatory tests should be performed before patients are informed about gonorrhoea diagnoses."
Response to Review 2
Thank you for asking me to review this paper that is investigating the use of dual tests for chlamydia and gonorrhoea on samples collected through the National Chlamydia Screening Programme. Given the increased availability of dual tests now and the potential issues around test performance for gonorrhoea in low prevalence populations, this paper is very timely and will be of great interest to policy makers and those working in the field. There is an urgent need for policy/guidelines around the use of these dual tests.
-Again, thank you for these supportive comments. We hope the study will be widely cited and used as evidence in designing testing policy. To this end, we have recently published revised gonorrhoea testing guidance in the UK, which is now cited in the paper (p.4) .
Specific comments are detailed below: 1) Introduction • For readers from outside of the UK, please briefly explain what a local authority is.
-
We have amended the text on p.4 as follows: "Since 2013, commissioning arrangements have been undertaken through Local Authorities, which are regional local government administrative bodies."
• Bottom of page 4……"Although the prevalence of gono in patients……..lack of confirmatory strategies means…….." Briefly explain why confirmatory testing is recommended for gonorrhoea testing and how this is tied into test performance, including positive predictive value.
-We have added the following text on p.4: "Where prevalence is low, the positive predictive value (PPV) of a single test will also be low, but the problem of low PPV can be resolved by undertaking a supplementary test on samples that initially screen positive."
• Top of page 5 -"A recent update to this survey….". It is not clear to which survey the authors are referring. Reference 17 could be a survey, but this is unclear. Who is Toby et al….perhaps some more detail of who/where this person is from.
-We have clarified that the reference is to a survey of laboratories and that the recent unpublished work repeats the original lab survey. The new work has been done by PHE and is currently being considered for publication elsewhere. The text on p.5 now reads: "In 2007, a laboratory survey found that 29% of hospital-based microbiology laboratories in England and Wales were already using dual tests to diagnose chlamydia and gonorrhoea.
[17] A recent repeat of this survey suggests this proportion has increased to 85% (Toby et al, Public Health England, unpublished study)."
2) Methods • It is unclear what an "upper tier" LA isplease explain, particularly for non-UK readers.
The following clarification has been added on p.5: "the 152 upper tier LAs in England (upper tier LAs are administrative bodies with a wide range of local government responsibilities, including for public health)".
• How many PHEs were invited? What was the response rate within PHE? -Sorry this was not clear. The first sentence of the results on p.7 now reads as follows: "Overall, 98/152 of LAs responded to the survey, which equates to a response rate across England of 64%."
• If a gonorrhoea test is NOT requested, do the laboratories still report on it to the requesting doctor/clinic? Or do they only report when the test is positive? Or do they only report on gonorrhoea when a dual test is requested?
-NCSP standards stipulate that laboratories should not test for any infection unless this has been specifically requested. We have added a short explanation to the results section on p.8, which also responds to the next comment, as follows: "NCSP standards stipulate that patients should be given specific information about any testing that is additional to chlamydia and that informed consent for such testing is obtained.
[23] The standards also recommend that laboratories should not test for any infection unless this has been specifically requested, and that patients diagnosed with gonorrhoea in community-based settings should usually be referred to a GUM clinic. [23] ."
• Please explain what happens to a patient diagnosed with gonorrhoeait seems from the paper, that those diagnosed with gonorrhoea are often referred to a GUM clinic for management/follow up.
-In most cases, patients diagnosed with gonorrhoea in community-based settings are referred to a GUM clinic. See text added above.
-The acronym has been removed from the paper.
• Please consider including a figure that shows the relationship between underlying gono prevalence and the number of false positive results that could arise assuming a set sensitivity and specificity…..it could be a simple column graph with prevalence on the x axis.
-We have already developed a tool for commissioners to estimate the number of false positive results in each area, given known GUM clinic prevalence for the area, and making reasonable assumptions about sensitivity and specificity. We've added a reference to this tool (p.11), but would rather avoid adding an additional figure because we had intended to include something similar in a methodological report describing how the tool was developed.
4) Discussion
• Top of page 9 -do you mean "powered" instead of "powerful"? -Yes, we had intended "powered". The text has been revised accordingly. 
